Stakeholders at the AXIS Patient Access Conference in Dublin heard that Ireland must agree a clear operational roadmap to meet its 180-day reimbursement decision target.
Gilead Sciences and Kite have announced the reimbursement of two CAR T-cell therapies in Ireland for eligible adult patients with certain relapsed or refractory blood cancers.
